VUMON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vumon, and when can generic versions of Vumon launch?
Vumon is a drug marketed by Hq Speclt Pharma and is included in one NDA.
The generic ingredient in VUMON is teniposide. There are two drug master file entries for this compound. Additional details are available on the teniposide profile page.
Summary for VUMON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 62 |
Patent Applications: | 2,377 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VUMON at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for VUMON
US Patents and Regulatory Information for VUMON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hq Speclt Pharma | VUMON | teniposide | INJECTABLE;INJECTION | 020119-001 | Jul 14, 1992 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |